Loading
Latest filing published 24 Feb 2026 for Vanda Pharmaceuticals Inc., €204k. Read the official filing
No signal scores available.
Tage Honore discloses dealings in Vanda Pharmaceuticals Inc. to SEC (Form 4). Between 15 March 2023 and 23 February 2026, the trades on record add up to 5 filings.
No open-market purchase appears, only 1 sale worth €204k. Outside the open market, there are 4 share grants. So far in 2026, the count stands at no purchases and 1 sale.
On 24 February 2026 came the latest disclosure, an open-market sale for €204k in Vanda Pharmaceuticals Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations